FOXP3 and neoplasm: The results of FoxP3+T cell immunofluorescence staining showed that the FoxP3+T cell content in the tumor tissue of osimertinib combined with the bevacizumab group was lower than that of the osimertinib single-agent group (Figures 5(e) and 5(f)).